PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Private equity-backed Covis to buy AMAG Pharma in $650M deal

  • Covis Group, a specialty pharmaceuticals company backed by private equity firm Apollo Global Management, has agreed to buy AMAG Pharmaceutical in a deal valued at approximately $650 million including debt, the companies announced Thursday.
  • Per deal terms, Covis will acquire all outstanding AMAG shares for $13.75 in cash, a price that values the drugmaker at a 46% premium to its closing price Wednesday. The companies expect the deal, worth $498 million on a fully diluated basis, to close in November 2020 following a tender offer. 
  • In AMAG, Covis acquires a company that’s struggled through a clinical setback for its top drug and a recent fight with activist investor Caligan Partners. In January, AMAG restructured, parting ways with its CEO and divesting two women’s health drugs. 

The company Covis is acquiring looks different than the AMAG of last year. 

A year ago, AMAG had just launched Vyleesi, a pill for low sexual desire in women and its third women’s health medicine alongside Makena, an injection to reduce the risk of preterm birth, and Intrarosa, a non-estrogen treatment for painful sex due to menopause. 

But investors, including Caligan Partners, were skeptical of the company’s path forward, particularly after Makena failed a key confirmatory study and a Food and Drug Administration panel recommended the drug’s withdrawal from market. 

In January, AMAG announced its CEO William Heiden would step down and that it would sell both Vyleesi and Intrarosa, divestments it completed in May and July of this year. 

Now, the company’s focus is weighted more heavily on Feraheme, a marketed product for iron deficiency anemia, and an experimental drug called ciraparantag. Currently in Phase 2 testing, ciraparantag is a reversal agent for blood thinners like Xarelto and Eliquis. 

Ami Fadia, an analyst at SVB Leerink, views ciraparantag as having the greatest potential of AMAG’s remaining assets, citing Alexion Pharmaceuticals’ recent $1.4 billion deal to buy Portola Pharmaceuticals and its similar reversal agent, Andexxa. 

Based in Switzerland, Covis Pharma sells a range of specialty pharmaceuticals and in February was sold to funds managed by affiliates of Apollo Global Management, a private equity firm. 

Covis’ proposed acquisition is the latest biotech buyout in a year that’s had comparatively fewer than 2019 and 2018 through September. Most recently, Gilead Sciences agreed to buy cancer drugmaker Immunomedics in the the biggest buyout of 2020.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026